- 15 April 2021Portfolio NewsAlchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
- 12 April 2021Portfolio NewsXilio Therapeutics Strengthens Management Team with R&D Leadership Appointments
- 16 March 2021Portfolio NewsAlchemab and Medicines Discovery Catapult to develop landmark novel antibody therapy for Huntington’s disease
- 24 February 2021Portfolio NewsXilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
- 23 November 2020Portfolio NewsCatamaran Bio Launches with $42 Million Financing to Develop Off-the-Shelf CAR-NK Cell Therapies to Treat Solid Tumors
- 10 November 2020Portfolio NewsXilio Therapeutics to Present Data on Tumor-Selective Immunotherapies at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
- 29 September 2020Portfolio NewsAlchemab partners with Amii to accelerate the development of novel therapeutics to cure disease
- 18 September 2020SV NewsSV Health Investors welcomes six new Venture Partners to the Biotech team
- 15 September 2020Portfolio NewsSV Health Investors announces launch of biotech portfolio company, Cellinta and the Company’s appointment of Dr Soraya Bekkali as CEO
- 7 September 2020SV NewsSV Health Investors (SV) announces the appointment of Alex Badamchi-Zadeh PhD, strengthening their transatlantic Biotech team
- 23 July 2020Portfolio NewsXilio Therapeutics Appoints Paul J. Clancy to its Board of Directors
- 20 July 2020SV NewsBritish Patient Capital commits $65m to SV Health Investors, to invest in life-changing biotechnology companies